Your browser doesn't support javascript.
loading
Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
Wang, Rong; Feng, Wenli; Wang, Hao; Wang, Lina; Yang, Xiao; Yang, Feifei; Zhang, Yingchi; Liu, Xiaoli; Zhang, Dongyue; Ren, Qian; Feng, Xiaoming; Zheng, Guoguang.
Afiliación
  • Wang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Feng W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Wang H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Wang L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Yang X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Yang F; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Zhang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Liu X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Zhang D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Ren Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Feng X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China.
  • Zheng G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China. Electronic address: zhengggtjchn
Cancer Lett ; 469: 151-161, 2020 01 28.
Article en En | MEDLINE | ID: mdl-31669202
Blocking the migration of regulatory T cells (Tregs) to the tumor microenvironment is a promising strategy for tumor immunotherapy. Treg accumulation in the leukemic hematopoietic microenvironment (LHME) has adverse impacts on patient outcomes. The mechanism and effective methods of disrupting Treg accumulation in the LHME have not been well established. Here, we studied the distribution and characteristics of Tregs in the LHME, investigated the effects of Treg ablation on leukemia progression, explored the mechanisms leading to Treg accumulation, and studied whether blocking Treg migration to the LHME delayed leukemia progression in MLL-AF9-induced mouse acute myeloid leukemia (AML) models using wildtype (WT) and Foxp3DTR/GFP mice. Increased accumulation of more activated Tregs was detected in the LHME. Inducible Treg ablation prolonged the survival of AML mice by promoting the antileukemic effects of CD8+ T cells. Furthermore, both local expansion and migration accounted for Treg accumulation in the LHME. Moreover, blocking the CCL3-CCR1/CCR5 and CXCL12-CXCR4 axes inhibited Treg accumulation in the LHME and delayed leukemia progression. Our findings provide laboratory evidence for a potential leukemia immunotherapy by blocking the migration of Tregs.
Asunto(s)
Antineoplásicos Inmunológicos/farmacología; Factores de Transcripción Forkhead/metabolismo; Leucemia Mieloide Aguda/tratamiento farmacológico; Linfocitos T Reguladores/efectos de los fármacos; Microambiente Tumoral/efectos de los fármacos; Adolescente; Traslado Adoptivo; Animales; Antineoplásicos Inmunológicos/uso terapéutico; Bencilaminas; Médula Ósea/patología; Movimiento Celular/efectos de los fármacos; Movimiento Celular/genética; Quimiocina CCL3/inmunología; Quimiocina CCL3/metabolismo; Quimiocina CXCL12/inmunología; Quimiocina CXCL12/metabolismo; Niño; Preescolar; Ciclamas; Modelos Animales de Enfermedad; Progresión de la Enfermedad; Femenino; Factores de Transcripción Forkhead/genética; Factores de Transcripción Forkhead/inmunología; Regulación Leucémica de la Expresión Génica/inmunología; Técnicas de Sustitución del Gen; Compuestos Heterocíclicos/farmacología; Compuestos Heterocíclicos/uso terapéutico; Humanos; Leucemia Mieloide Aguda/genética; Leucemia Mieloide Aguda/inmunología; Leucemia Mieloide Aguda/patología; Masculino; Maraviroc/farmacología; Maraviroc/uso terapéutico; Ratones; Ratones Transgénicos; Proteína de la Leucemia Mieloide-Linfoide/genética; Proteínas de Fusión Oncogénica/genética; Receptores CCR/antagonistas & inhibidores; Receptores CCR/metabolismo; Transducción de Señal/efectos de los fármacos; Transducción de Señal/genética; Transducción de Señal/inmunología; Linfocitos T Reguladores/inmunología; Linfocitos T Reguladores/metabolismo; Linfocitos T Reguladores/patología; Microambiente Tumoral/genética; Microambiente Tumoral/inmunología
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Linfocitos T Reguladores / Factores de Transcripción Forkhead / Microambiente Tumoral / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Lett Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Linfocitos T Reguladores / Factores de Transcripción Forkhead / Microambiente Tumoral / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Lett Año: 2020 Tipo del documento: Article País de afiliación: China
...